Mutual of America Capital Management LLC Sells 860 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Mutual of America Capital Management LLC cut its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 6.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,218 shares of the biopharmaceutical company's stock after selling 860 shares during the period. Mutual of America Capital Management LLC's holdings in Regeneron Pharmaceuticals were worth $7,749,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in REGN. Pinney & Scofield Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $25,000. E Fund Management Hong Kong Co. Ltd. grew its stake in shares of Regeneron Pharmaceuticals by 344.4% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 31 shares during the last quarter. Tompkins Financial Corp bought a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth $32,000. Curat Global LLC bought a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth $32,000. Finally, American National Bank & Trust bought a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth $44,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Up 0.6%

Shares of NASDAQ REGN traded up $3.20 during trading on Friday, hitting $563.00. 1,024,297 shares of the company traded hands, compared to its average volume of 1,116,347. The business's fifty day moving average is $535.40 and its 200 day moving average is $600.61. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $1,211.20. The firm has a market capitalization of $60.78 billion, a price-to-earnings ratio of 14.19, a P/E/G ratio of 1.91 and a beta of 0.33. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.73 and a current ratio of 4.60.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping the consensus estimate of $8.43 by $4.46. The company had revenue of $3,675,600 billion during the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm's revenue for the quarter was up 3.6% on a year-over-year basis. During the same period in the previous year, the firm posted $11.56 earnings per share. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals's payout ratio is presently 8.87%.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on REGN. Royal Bank Of Canada boosted their price objective on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a "sector perform" rating in a research note on Monday. BMO Capital Markets boosted their price objective on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an "outperform" rating in a research note on Monday. Canaccord Genuity Group reissued a "buy" rating and issued a $850.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, July 23rd. JPMorgan Chase & Co. reduced their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a research note on Monday, June 9th. Finally, Wells Fargo & Company cut shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price objective on the stock. in a research note on Friday, August 1st. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $841.30.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.